glp 1 pill eli lilly Founday (orforglipron), the new oral GLP-1 for weight loss, now available in the U.S. - Eli Lilly’s experimental pill, orforglipron,

announced new data from its Phase I clinical trial of zerlasiran (formerly SLN360), an siRNA therapeutic targeting Lp(a), which showed that within 90 days of two subcutaneous administrations, patients experienced a significant reduction in Lp(a) levels compared to baseline, which was as much as 99% lower and well tolerated [236]

Mechanistically, lanosterol administration increased the solubility of lens proteins and reduced oxidative stress by enhancing total antioxidant capacity and decreasing GSSG/GSH ratio in the lens cortex (150), and its effect was dependent on the severity of the condition or the lanosterol concentration in aqueous humor which varies from 0 to 31.61 ng/ml (150,153)

What should I tell my MIVM-affiliated provider before using tirzepatide

Further studies with increased sample size and efforts to identify the metabolite markers by a more sensitive complementary method such as mass spectrometry can be used to further corroborate these findings